<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048589</url>
  </required_header>
  <id_info>
    <org_study_id>DANFLU-1</org_study_id>
    <secondary_id>QHD00027</secondary_id>
    <secondary_id>2021-003170-31</secondary_id>
    <nct_id>NCT05048589</nct_id>
  </id_info>
  <brief_title>Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting</brief_title>
  <acronym>DANFLU-1</acronym>
  <official_title>Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tor Biering-Sørensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the feasibility of identifying, recruiting and&#xD;
      randomizing a large sample of Danish citizens aged 65-79 years to high-dose quadrivalent&#xD;
      influenza vaccine or standard-dose quadrivalent influenza vaccine in the 2021/2022 influenza&#xD;
      season in a registry-based setting using Danish nationwide registries for all data collection&#xD;
      including baseline information and outcome assessment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the feasibility of recruiting and randomizing Danish citizens aged 65-79 years,&#xD;
      we aim to randomize 40,000 citizens 1:1 to high-dose quadrivalent influenza vaccine or&#xD;
      standard-dose quadrivalent influenza vaccine in a pragmatic, open-label, registry-based&#xD;
      design using the infrastructure of Danske Lægers Vaccinations Service (DLVS), an organization&#xD;
      responsible for numerous vaccination clinics in Denmark, for recruitment and randomization&#xD;
      and Danish nationwide registries for data collection. Citizens will be recruited by DLVS and&#xD;
      randomized and vaccinated at the DLVS clinics. All collection of data related to baseline&#xD;
      information, outcomes, and safety monitoring will be performed by a central trial site&#xD;
      utilizing information from Danish nationwide health registries.&#xD;
&#xD;
      The findings of this pilot trial will indicate whether the conduction of a full-scale,&#xD;
      adequately powered pragmatic RCT is feasible within the Danish registry-based framework.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of persons contacted by recruitment letter</measure>
    <time_frame>Up to 8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants included and randomized to QIV-HD or QIV-SD</measure>
    <time_frame>Up to 8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Agreement between randomization assignment and actual received vaccine</measure>
    <time_frame>Up to 8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Balance between groups in terms of number of subjects in each arm and baseline characteristics</measure>
    <time_frame>Up to 8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of baseline characteristics for the QIV-HD and QIV-SD groups to the overall Danish general population aged 65-79 years</measure>
    <time_frame>Up to 8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of baseline characteristics for the QIV-HD and QIV-SD groups to the population aged 65-79 years in the DLVS database used for recruitment</measure>
    <time_frame>Up to 8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of event rates and calculation of relative vaccine effectiveness for hospitalization for influenza and/or pneumonia</measure>
    <time_frame>&gt;= 14 days after vaccination up to 8 months post-vaccination</time_frame>
    <description>First hospitalization with a primary (A) diagnosis code for influenza or pneumonia of at least 1 night duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of event rates and calculation of relative vaccine effectiveness for hospitalization for respiratory disease</measure>
    <time_frame>&gt;= 14 days after vaccination up to 8 months post-vaccination</time_frame>
    <description>First hospitalization with a primary (A) diagnosis code for respiratory disease of at least 1 night duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of event rates and calculation of relative vaccine effectiveness for hospitalization for cardio-respiratory disease</measure>
    <time_frame>&gt;= 14 days after vaccination up to 8 months post-vaccination</time_frame>
    <description>First hospitalization with a primary (A) diagnosis code for cardio-respiratory disease of at least 1 night duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of event rates and calculation of relative vaccine effectiveness for hospitalization for cardiovascular disease</measure>
    <time_frame>&gt;= 14 days after vaccination up to 8 months post-vaccination</time_frame>
    <description>First hospitalization with a primary (A) diagnosis code for cardiovascular disease of at least 1 night duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of event rates and calculation of relative vaccine effectiveness for hospitalization from any cause</measure>
    <time_frame>&gt;= 14 days after vaccination up to 8 months post-vaccination</time_frame>
    <description>First hospitalization with any diagnosis code of at least 1 night duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of event rates and calculation of relative vaccine effectiveness for all-cause mortality</measure>
    <time_frame>&gt;= 14 days after vaccination up to 8 months post-vaccination</time_frame>
    <description>Death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of event rates and calculation of relative vaccine effectiveness for hospitalization for COVID-19</measure>
    <time_frame>&gt;= 14 days after vaccination up to 8 months post-vaccination</time_frame>
    <description>First hospitalization with a primary (A) diagnosis code for COVID-19 of at least 1 night duration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40000</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Standard-Dose Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QIV-SD single injection at Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QIV-HD single injection at Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard-Dose Quadrivalent Influenza Vaccine</intervention_name>
    <description>For the control arm, the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used.</description>
    <arm_group_label>Standard-Dose Quadrivalent Influenza Vaccine</arm_group_label>
    <other_name>QIV-SD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-Dose Quadrivalent Influenza Vaccine</intervention_name>
    <description>For the control arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.</description>
    <arm_group_label>High-Dose Quadrivalent Influenza Vaccine</arm_group_label>
    <other_name>QIV-HD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 65-79 years&#xD;
&#xD;
          2. Informed consent form has been signed and dated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Allergy/hypersensitivity towards the influenza vaccines used in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tor Biering-Sørensen, MD, PhD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Research Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niklas Dyrby Johansen, MD</last_name>
    <phone>+4520204794</phone>
    <email>niklas.dyrby.johansen@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niklas Dyrby Johansen, MD</last_name>
      <phone>+4520204794</phone>
      <email>niklas.dyrby.johansen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Tor Biering-Sørensen, MD, PhD, MPH</last_name>
      <phone>+4528933590</phone>
      <email>tor.biering-soerensen@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Tor Biering-Sørensen, MD, PhD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danske Lægers Vaccinations Service</name>
      <address>
        <city>Søborg</city>
        <zip>2860</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten S Larsen, MD, DMSc</last_name>
    </contact>
    <investigator>
      <last_name>Carsten S Larsen, MD, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev and Gentofte Hospital</investigator_affiliation>
    <investigator_full_name>Tor Biering-Sørensen</investigator_full_name>
    <investigator_title>Research Director, MD, PhD, MPH</investigator_title>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Pragmatic</keyword>
  <keyword>Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Sharing of individual-level data stemming from Danish administrative registries is illegal according to Danish law.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

